Abstract:A series of thiadiazole derivatives was designed, synthesized, and evaluated as potential cholinesterase inhibitors for the treatment of Alzheimer's disease. Among them, compound 11 u showed potent inhibitory effects on cholinesterase, with superior AChE inhibitory activity (IC50=2.73 μM) and BChE inhibitory activity (IC50=0.65 μM) compared to galantamine used as the control compound. A series of thiadiazole derivatives were designed and synthesized as dual inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) for the treatment of Alzheimer's disease (AD). Furthermore, the compounds were assayed for their inhibitory activity to AChE and BuChE in vitro, and the results indicated that most of the compounds had moderate inhibitory activity to AChE and BuChE. Among them, compound 11 u showed the best inhibitory activity against AChE and BuChE (eeAChE, IC50=2.73 μM; eqBuChE, IC50=0.65 μM), which showed approximately 2‐fold more activity against AChE enzyme than galantamine and approximately 28‐fold more activity against BuChE enzyme than galantamine. In addition, molecular docking studies have shown that compound 11 u could bind to the catalytic active site (CAS) and peripheral anion site (PAS) of AChE and BuChE. Among them, compound 11 u combined with BuChE and exhibited a mixed inhibition pattern consistent with enzyme kinetics studies. The interaction's stability of 11 u‐AChE/BuChE were also assessed using a conventional atomistic 100 ns dynamics simulation study, which revealed the conformational stability of representative compound 11 u in the cavity of the AChE/BuChE. Moreover, the molecular properties of all compounds were predicted by online through the SwissADME, and the best active compound 11 u matched the properties of most orally administered drugs. All these suggested that 11 u could be considered as a lead compound for the development of drugs for AD.

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

N-Benzyl Benzamide Derivatives As Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease

Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning As Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase

Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, synthesis and biological evaluation of novel pyrazolone derivatives as selective butyrylcholinesterase inhibitors with antioxidant activity against Alzheimer's disease

Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors

N -Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer's Disease

Design, Synthesis and Biological Evaluation of 1-Phenyl-ethanone Derivatives for Multi-Targeted Treatment of Alzheimer's Disease

Evaluation Of Novel Dual Acetyl- And Butyrylcholinesterase Inhibitors As Potential Anti-Alzheimer'S Disease Agents Using Pharmacophore, 3d-Qsar And Molecular Docking Approaches

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Novel Thiadiazole Derivatives as Potential Anti‐Alzheimer Agent: Synthesis, Activity of Molecular Interactions and their in Silico Assessment

Synthesis and Biological Evaluation of 2-Arylbenzofuran Derivatives As Potential Anti-Alzheimer's Disease Agents.

Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer's disease

Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (ache) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease

Design, Synthesis and Biological Evaluation of Dual Acetyl Cholinesterase and Beta-Secretase Inhibitors in Treatment for Alzheimer's Disease.